Osivelotor
- Generic Name
- Osivelotor
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N2O6
- CAS Number
- 2417955-18-9
- Unique Ingredient Identifier
- UK749B4S16
A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT06507904
A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver Function
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT06340347
- Locations
- ๐บ๐ธ
Orange County Research Center, Lake Forest, California, United States
๐บ๐ธGenesis Clinical Research, LLC, Tampa, Florida, United States
๐บ๐ธThomas Jefferson University-Pharmacology, Physiology and Cancer Biology, Philadelphia, Pennsylvania, United States
A Study to Learn How Different Products of the Study Medicine Called PF-07940367 Are Taken up Into the Blood in Healthy Adults
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT06190561
- Locations
- ๐บ๐ธ
Anaheim Clinical Trials, LLC, Anaheim, California, United States
Study of GBT021601 in Participants With Renal Impairment
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT05878704
- Locations
- ๐บ๐ธ
Orange County Research Center, Tustin, California, United States
๐บ๐ธAdvanced Pharma CR, LLC, Miami, Florida, United States
๐บ๐ธNucleus Network, Saint Paul, Minnesota, United States
A GBT021601 ADME Microtracer Study in Healthy Volunteers
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT05718687
- Locations
- ๐ณ๐ฑ
ICON Early Phase Clinic, LLC, Groningen, Netherlands
GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 47
- Registration Number
- NCT05632354
- Locations
- ๐บ๐ธ
Our Lady of the Lake Hospital, Inc., Baton Rouge, Louisiana, United States
๐บ๐ธUniversity Medical Center New Orleans, New Orleans, Louisiana, United States
๐บ๐ธMississippi Center for Advanced Medicine, Madison, Mississippi, United States
A Phase 2/3 Study in Adult and Pediatric Participants With SCD
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 429
- Registration Number
- NCT05431088
- Locations
- ๐บ๐ธ
LSU Health Baton Rouge-North Clinic, Baton Rouge, Louisiana, United States
๐บ๐ธOur Lady of the Lake Hopistal, Inc, Baton Rouge, Louisiana, United States
๐บ๐ธOur lady of the Lake Hospital, Baton Rouge, Louisiana, United States
A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 129
- Registration Number
- NCT05036512
- Locations
- ๐ฆ๐บ
Harry Perkins Institute of Medical Research, Nedlands, Western Australia, Australia
๐ฆ๐บLinear Clinical Research, Nedlands, Western Australia, Australia
๐บ๐ธICON Early Phase Services, LLC, San Antonio, Texas, United States
A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT04983264
- Locations
- ๐บ๐ธ
Advanced Pharma CR, LLC, Miami, Florida, United States
๐บ๐ธChildren's Healthcare of Atlanta AFLAC Center, Atlanta, Georgia, United States
๐บ๐ธVisionaries Clinical Research LLC, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.